Galapagos NV

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

26 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Galapagos announces full year 2023 results and outlook for 2024

22 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Galapagos presents at EBMT-EHA annual meeting 2024

15 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

31 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

04 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

03 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

02 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

19 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

09 Dec 2023 12:00:00 By Nasdaq GlobeNewswire

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

07 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

02 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

30 Oct 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos appoints Simon Sturge to its Board of Directors

19 Sep 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus  

28 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos announces first half-year 2023 financial results

03 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

15 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

12 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

05 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis

23 May 2023 16:01:00 By Nasdaq GlobeNewswire

Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023

22 May 2023 16:01:00 By Nasdaq GlobeNewswire